Clinical Trials Logo

Clinical Trial Summary

Idiopathic hypersomnia (IH) is a rare and poorly studied disease characterized by excessive daytime sleepiness different from that of narcolepsy (sleep drunkness non-recuperative naps and nocturnal blackout). Local sleep is a recent concept, proposing a local regulation of the sleep-wake state, characterized by slow waves (SW) restricted to certain regions of a globally awake brain. The investigators are going to investigate whether local sleep could explain the sleepiness of these patients better than the global occurrence of sleep which are not very frequent during daytime tests in IH. The investigators propose to look for local sleep through the detection of local slow waves in the EEG of resting wakefulness and during an attentional task in people with IH compared to people with NT1 (sleepy, but with a different type of sleepiness from IH, more abrupt and including REM sleep) and non sleepy people.


Clinical Trial Description

Local sleep is a recent concept, suggesting a local regulation of the sleep-wake state, characterized for example in wakefulness by slow waves restricted to certain regions of a globally awake brain, correlating with modifications of mental experience and behavior. Although the phenomenon of local sleep has been demonstrated following acute sleep deprivation, its importance in explaining attentional fluctuations during a normal day is only beginning to be investigated. Moreover, inter-individual variations remain unexplored. The investigators propose to study in EEG (64 electrodes) the occurrence of local sleep in different states of sleepiness, in particular in idiopathic hypersomnia (IH) in comparison to that of narcolepsy type 1 (NT1) and to non-drowsy individuals, both in the resting state and during a sustained attention test (SART). This study will provide a better understanding of intra- (over the course of a day) and inter-individual fluctuations in the local sleep phenomenon potentially involved in this disease and its impact on cognition. Anticipated number of participants: 60 including: - 20 people with idiopathic hypersomnia - 20 people with type 1 narcolepsy - 20 people with no previous history Practical procedure: Single visit: presence from 9:30 am to 3:30 pm - General questionnaire on sleep habits and symptoms. - Equipment: EEG 32 electrodes, EOG, ECG, eye tracker and thoracoabdominal belts. - Morning and afternoon recording: 10 minutes in resting state, 60 minutes of digital SART (go-no-go test in front of a screen, with intermittent evaluation of mental state), then 10 minutes of rest. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06153615
Study type Interventional
Source Assistance Publique - Hôpitaux de Paris
Contact Isabelle Arnulf, MD, PhD
Phone 01 42 16 77 04
Email isabelle.arnulf@aphp.fr
Status Not yet recruiting
Phase N/A
Start date December 2023
Completion date May 2024

See also
  Status Clinical Trial Phase
Recruiting NCT04026958 - Clarithromycin Mechanisms in Hypersomnia Syndromes Phase 2
Completed NCT02512588 - A Study of Safety and Efficacy of BTD-001 in Treatment of Patients With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2 Phase 2
Completed NCT01183312 - Flumazenil for the Treatment of Primary Hypersomnia Phase 1/Phase 2
Completed NCT03597555 - Sodium Oxybate in Idiopathic Hypersomnia Phase 2/Phase 3
Completed NCT03356938 - The Role of the Circadian System in Neurological Sleep-wake Disorders N/A
Completed NCT03533114 - A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension Phase 3
Active, not recruiting NCT03542851 - A Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia Phase 2
Completed NCT05156047 - A Phase 3 Study to Assess the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia Phase 3
Enrolling by invitation NCT05371483 - Cardiovascular and Cognitive Implications of Central Disorders of Hypersomnolence and Their Treatments
Not yet recruiting NCT06252571 - a Chronobiological Treatment Combining Evening Melatonin and Morning Light Therapy in Idiopathic Hypersomnia: a Prospective, Double Bind, Randomized, Placebo-controlled -Trial Phase 2
Completed NCT04827329 - Anesthetic Management of Patients With Chronic Sleep Disorders
Recruiting NCT05875974 - Ph4 PSG Combined JZP258-407 Phase 4
Recruiting NCT01793168 - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Completed NCT01146600 - Clarithromycin for the Treatment of Hypersomnia Phase 2
Recruiting NCT04330963 - International Swiss Primary Hypersomnolence and Narcolepsy Cohort Study
Not yet recruiting NCT05615584 - Spectrometry (MRM) Versus I 125 Radioimmunoassay (RIA) for Quantification of Orexin-A of Patients With Hypersomnolence N/A
Completed NCT04091438 - A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia Phase 1
Recruiting NCT05837091 - Low Sodium Oxybate in Patients With Idiopathic Hypersomnia Phase 4
Recruiting NCT05321355 - Mainz Register of Patients With Sleep Disorders
Active, not recruiting NCT05668754 - Placebo-Controlled, Double-Blind, Study to Determine the Safety and Efficacy of SDX in Patients With IH Phase 2